Theravance axing 75% of staff, slashing R&D budget after flunking phase 3

Theravance Biopharma’s rotten run has triggered big changes at the biotech. With a phase 3 rare disease study becoming the third trial to fail in as many months, Theravance is axing 75% of its staff and narrowing its focus to respiratory diseases.